Pfizer Inc. (NYSE:PFE) Shares Bought by Sienna Gestion

Sienna Gestion grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 221,295 shares of the biopharmaceutical company’s stock after acquiring an additional 1,771 shares during the period. Sienna Gestion’s holdings in Pfizer were worth $6,189,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Gilbert & Cook Inc. boosted its position in shares of Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 945 shares in the last quarter. Gryphon Financial Partners LLC lifted its holdings in shares of Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 8,194 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $186,000. Aigen Investment Management LP purchased a new position in shares of Pfizer during the 4th quarter worth approximately $867,000. Finally, InterOcean Capital Group LLC increased its stake in shares of Pfizer by 5.3% during the 4th quarter. InterOcean Capital Group LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $745,000 after purchasing an additional 1,291 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $29.75 on Thursday. The company has a market cap of $168.58 billion, a P/E ratio of -495.75, a P/E/G ratio of 1.02 and a beta of 0.68. The firm’s 50 day moving average is $29.33 and its two-hundred day moving average is $28.19. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the company posted $0.67 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.65%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.